Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

NCT03182166 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Golimumab (Optimization)
DIAGNOSTIC_TEST: Rectosigmoidoscopy
BIOLOGICAL: Blood samples

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Collaborators

[object Object]